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We conducted a large population-based retrospective cross-sectional study for determining the
extent of clinically recognized chronic obstructive pulmonary disease (COPD) and asthma, and
the prevalence of associated cardiovascular diseases (CVDs), using information obtained from
the Health Search Database (HSD) owned by the Italian College of General Practitioners (SIMG).
Our study provides further evidence that patients with the diagnosis of COPD are at increased
association with the diagnosis of most CVDs. It also documents that age clusters between 35
and 54 years are those at highest association of simultaneous presence of the diagnosis of
CVD and that of COPD, with a progressive significant reduction in older age clusters. Moreover,
it shows that the diagnosis of asthma is modestly associated with the diagnosis of different CV
morbidities.
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Chronic obstructive pulmonary disease (COPD) and asthma
are conditions associated with many comorbidities at the
time of diagnosis.1e5 In particular, there is solid evidence
that patients with COPD are at increased risk of cardio-
vascular disease (CVD),3,6e8 whereas the link between
asthma and CVD seems to be less strong,5,9e11 and some
researchers deny the existence of this link.12,13
In the current study, we determined the extent of clin-
ically recognized COPD and asthma, and the prevalence of
associated CVDs using information obtained from the Health
Search Database (HSD) owned by the Societa` Italiana Medici
Generici (SIMG), the Italian College of General Practi-
tioners, which stores information on about 1.5% of the total
Italian population served by general practitioners (GPs).
Patients and methods
Collection of information
We conducted a population-based retrospective cross-
sectional study using information obtained from the HSD.
Primary-care data were obtained from the HSD of SIMG.
Established in 1998 with the primary aim to carry out
observational studies on the incidence and prevalence of
chronic diseases and with the input of GPs who accept to
participate on a voluntary basis, the HSD contains infor-
mation provided by more than 650 GPs from all Italian
regions. It included a total of 909,638 individuals (429,962
men and 479,676 women) aged >14 years and registered in
the HSD at the end of December 2009.14
After intensive training, all participating GPs had to use
specially designed software to record data during their
normal daily clinical practice (Millewin). The software
system codes all the diagnostic records by using the Clas-
sification of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM).15 Prescription records are also coded according
to the anatomical therapeutic chemical (ATC) classification
system. Data are recorded in the HSD with the consent of
the patient, lawfully stored, managed according to privacy
rules and can be used for scientific studies without any
further authorization from an ethics committee.
It is well known that before using any data resource,
particularly one that is based on computer records, it is
necessary to determine the quality and completeness of
the available information. Therefore, data are subject to
a range of quality checks. Any variations within agreed
ranges are investigated and submitted to each participating
GP. Physicians who fail to meet standard quality criteria are
not considered for epidemiological studies.16
We must highlight that comparative analyses have
demonstrated the validity of the information gathered in
the HSD.17
Ascertainment of COPD, asthma and comorbidities
Cases of COPD were identified on the basis of the ICD-9
codes 491, 492, and 496, and those of asthma on the basis
of the ICD-9 code 493. The number of patients classified onthe basis of the ICD-9 code 493.2 was really small and for
this reason we have not considered it separately also for
avoiding a statistical bias. Unfortunately we have not
information related to temporality in HSD.
Always using the ICD-9 codes, we regarded as cardio-
vascular comorbidities cases of hypertensive disease
(401e405), ischemic heart disease (410e414), diseases of
pulmonary circulation (415e417), other forms of heart
disease (420e429), cardiac arrhythmia (427), heart failure
(428), cerebrovascular diseases (430e438).
Analysis
The study was carried out by a cross-sectional and obser-
vational field method. It permitted to describe the situation
at the time of data collection, at the end of December
2009, and it allowed determining the prevalence of inves-
tigated outcomes. The studied population was divided by
several clusters: age (35e44, 45e54, 55e64, 65e74, 75e84
and older than 85 years old), gender (male and female),
and comorbidities.
We evaluated the odds ratio (OR) that was chosen
instead of relative risk (RR) because asthma and COPD have
a prevalence that is less than 10%.18,19 Positive and nega-
tive OR values mean a co-relative positive and negative
association between evaluated variables. Data were
adjusted for sex and age by Mantel-Haenszel method, that
permits a precision-based estimates of the OR. Further-
more, if the prevalence of comorbidities were more than
10%, and the OR was more than 2.5 or less than 0.5,
correction of the OR was carried out.18,19 In order to
calculate statistical and epidemiological values, computer
software GraphPad Prism (CA, USA), SPSS (Chicago, IL, USA)
and OpenEpi (Dean AG, Sullivan KM, Soe MM. Open Source
Epidemiologic Statistics for Public Health) were used.
Results
We excluded the age cluster 15e34 years because in this
population the risk of COPD was not relevant.14 We iden-
tified a population of 690,489 individuals aged >34 years
and registered in the HSD at the end of December 2009.
There were 39,741 (5.76% of the entire population) indi-
viduals suffering from asthma and 25,281 (3.66% of the
entire population) patients with a diagnosis of COPD. The
prevalence of asthma was greater in women than in men
with a men/women ratio of 0.71, whereas the prevalence
of COPD was greater in men than in women with a men/
women ratio of 1.64, and increased with age in both men
and women.
Association between asthma, COPD and CV
morbidities
Table 1 shows the demographic characteristics of the study
population by age distribution, asthma, COPD and CV
morbidities. All individuals that were not identified on the
basis of the ICD-9 code 493 were considered “non-asth-
matics”, whereas all subjects that were not identified on
the basis of the ICD-9 codes 491, 492, and 496 were
considered “non-COPD patients”.
Table 1 Demographic characteristics of study population by age distribution, the diagnosis of asthma, COPD and CV
morbidities. A: number of subjects, B: prevalence (%).
A General population
(total)
General population
(non-asthmatic and non-
COPD patients)
Asthma COPD
35e44 167,191 156,284 10,123 784
45e54 156,279 144,866 9434 1979
55e64 135,376 123,471 7709 4196
65e74 113,465 99,742 6568 7155
75e84 84,196 71,589 4506 8101
>85 33,982 29,515 1401 3066
Total 690,489 625,467 39,741 25,281
B General population
(total)
General population
(non-asthmatic and
non-COPD patients)
Asthma COPD General
population
(total)
General population
(non-asthmatic and
non-COPD patients)
Asthma COPD
Angina and coronary disease Acute or old myocardial infarction
35e44 0.12 0.11 0.13 0.89 0.11 0.11 0.06 0.13
45e54 0.65 0.61 0.91 2.27 0.56 0.54 0.59 1.67
55e64 2.40 2.24 2.97 6.22 1.69 1.66 1.28 3.55
65e74 4.63 4.24 5.91 8.93 2.88 2.73 2.51 5.37
75e84 7.24 6.54 9.92 11.95 3.96 3.70 4.37 6.01
>85 8.17 7.46 11.92 13.27 3.92 3.76 4.28 5.25
Cardiac arrhythmia Heart failure
35e44 2.12 2.07 2.88 2.17 0.04 0.03 0.08 0.38
45e54 3.32 3.18 5.12 4.70 0.14 0.12 0.29 0.91
55e64 5.11 4.85 7.64 7.96 0.51 0.41 1.02 2.62
65e74 9.35 8.79 12.85 13.92 1.49 1.17 2.57 5.02
75e84 15.64 14.68 20.06 21.64 4.38 3.58 7.15 9.91
>85 17.38 16.32 24.13 24.49 8.66 7.41 15.92 17.32
Hypertension disease Cerebrovascular disease
35e44 6.78 6.58 9.52 12.24 0.09 0.09 0.13 0.26
45e54 19.96 19.37 26.08 33.80 0.33 0.31 0.49 0.71
55e64 39.54 38.59 48.88 50.45 1.07 1.03 1.60 1.43
65e74 54.87 53.79 63.11 62.35 3.04 2.92 3.90 3.80
75e84 62.73 61.92 69.09 66.30 6.96 6.91 9.21 6.17
>85 58.63 57.56 68.81 64.22 10.11 10.29 13.49 6.88
Other heart disease Pulmonary embolism
35e44 0.06 0.05 0.14 0.38 0.04 0.04 0.06 0.13
45e54 0.12 0.10 0.24 0.35 0.07 0.07 0.13 0.20
55e64 0.18 0.17 0.29 0.38 0.13 0.12 0.25 0.36
65e74 0.34 0.29 0.58 0.80 0.28 0.24 0.53 0.55
75e84 0.50 0.42 0.84 0.96 0.70 0.63 1.11 1.10
>85 0.62 0.60 0.50 0.85 0.82 0.78 1.28 0.91
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myocardial infarction, angina and coronary disease, cardiac
arrhythmia, heart failure, cerebrovascular disease, other
heart disease, or pulmonary embolism) with their preva-
lences in the general population and in patients with the
diagnosis of asthma or COPD. We also show the data of
hypertensive disease with its prevalence in the general
population and in patients with the diagnosis of asthma or
COPD.
The diagnosis of COPD was significantly associated with
an increased likelihood of diagnosis of CVD and hyperten-
sive disease (Fig. 1B). On the contrary, although CVD and
hypertensive disease were more prevalent in patients with
diagnosis of asthma than in the general population (Table2), apparently asthma had a weak association with these
diseases (Fig. 1A).
Intriguingly, the adjusted OR for acute or old myocardial
infarction was 0.98 (95% CI 0.90e1.07) in patients with the
diagnosis of asthma and 2.91 (95% CI 2.74e3.09) in those
with the diagnosis of COPD.Impact of gender on CVD in asthma and COPD
CV morbidities in the general population affected slightly
more women than men, with an adjusted men/women ratio
of 0.98. The ration was balanced in COPD (1.00), but it
decreased in asthma (0.95) indicating a higher prevalence
Table 2 Demographic characteristics of study population by prevalence of CV morbidities in the general population, and in
patients with the diagnosis of asthma or COPD (%).
General population
(total)
General population
(non-asthmatic and
non-COPD patients)
Asthma COPD
Total Men Women Total Men Women Total Men Women Total Men Women
Angina and
coronary disease
2.69 3.46 2.03 2.39 3.07 1.80 3.35 4.10 2.89 9.20 10.42 7.48
Acute or old
myocardial infarction
1.63 2.56 0.83 1.52 2.38 0.77 1.47 2.47 0.85 4.81 6.30 2.69
Cardiac arrhythmia 6.56 6.29 6.80 6.06 5.72 6.36 8.68 8.33 8.90 15.60 15.53 15.71
Heart failure 1.35 1.32 1.37 1.06 0.98 1.13 2.08 2.03 2.12 7.21 7.13 7.33
Hypertension disease 33.46 31.78 34.92 32.13 30.33 33.68 38.79 36.02 40.49 58.08 55.79 61.33
Cerebrovascular disease 2.15 1.91 2.37 2.04 1.95 2.12 2.62 2.25 2.85 4.19 0.76 9.03
Other heart disease 0.22 0.23 0.22 0.19 0.19 0.20 0.36 0.37 0.35 0.74 0.76 0.71
Pulmonary embolism 0.22 0.20 0.24 0.20 0.18 0.22 0.35 0.32 0.37 0.70 0.61 0.82
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of hypertensive disease in women, with a greater impact in
COPD (men/women ratio: 0.91 in the general population,
0.91 in COPD, and 0.89 in asthma, respectively).
Among patients with the diagnosis of asthma, there was
not difference in gender for association with all CVDs,
excluded for angina and coronary disease, for which the OR
was higher in women compared to men (Fig. 1A).
Among patients with the diagnosis of COPD, there were
not differences in gender for association with all CVDs,
excluded for acute or old myocardial infarction and angina
and coronary disease, for which the OR was higher in
women compared to men (Fig. 1B).
Impact of age on CVDs in patients with the diagnosis
of asthma or COPD
Both in patients with the diagnosis of asthma and in those
with the diagnosis of COPD, an increase in age resulted in
a progressive increase in the prevalence of the diagnosis of
CVD and hypertensive disease. However, while the
different age clusters did not affect differently the CV
morbidities in asthma, clusters between 35 and 54 years
were those at highest correlation with the simultaneous
presence of the diagnoses of CV morbidities and COPD, with
a progressive significant reduction in older age clusters.
Intriguingly, the age cluster 35e44 years caused the highest
ORs for angina and coronary disease, heart failure, and
cerebrovascular disease, and that 45e54 years caused the
highest correlation with acute or old myocardial infarction.
Age did not influence differently the association with
cardiac arrhythmia, although there was a decrease of
adjusted OR in the age cluster 35e44. Fig. 2 illustrates the
ORs of diagnoses of CVD and hypertensive both in patients
with the diagnosis of asthma and in those with the diagnosis
of COPD according to the different age clusters.
Impact of smoking habits on CVD in patients with
the diagnosis of asthma or COPD
Table 3 shows the demographic characteristics of the study
population by smoking status (never smokers, current-smokers and former smokers) and by the diagnosis of
asthma and COPD. As expected, there were differences of
smoking habit between general population and COPD, on the
contrary the prevalence of smoking habits in asthmatics was
analogous to that in general population. In particular,
smoking prevalence was higher in COPD compared to asth-
matics (COPD/asthma ratio: 1.45, current-smokers; 1.63,
former smokers), whereas never smokers were the majority
in asthmatics (COPD/asthma ratio: 0.57, never smokers).
In patients with the diagnosis of asthma, the smoking
habit did not modify the prevalence of CVD, compared to
the general population. On the contrary, in patients with
the diagnosis of COPD the overall prevalence of CVD was
more than double in current and former smokers and it
increased by more than five-fold in never smokers,
compared to the general population (Table 4).
The analysis of the putative interference of smoking
habit on the association with CVD showed that the smoking
habit represented neither a bias nor a confounding factor.
In fact, the diagnosis of COPD increased by 2.6 folds and
significantly (P < 0.05) the overall correlation with CVD in
never-smokers compared to current and former smokers,
versus the general population. On the contrary, the diag-
nosis of asthma did not modify the OR of CVD by clustering
for smoking habit (Table 5).Discussion
This large observational study is the first, to the best of our
knowledge, that has explored the difference in prevalence
of the diagnosis of CVD between patients with and without
diagnoses of COPD or asthma performing stratified analyses
by age or gender. It documents that the diagnosis of asthma
is modestly correlated with the diagnosis of different CV
morbidities and provides further evidence that patients
with the diagnosis of COPD are highly associated with the
diagnoses of CVDs. Moreover, it suggests that the diagnosis
of COPD is strongly associated with that of CVD, regardless
the smoking habit.
We believe that the additional information to the
possible, although weak, association between the diag-
noses of asthma and CVD is important because, as already
Figure 1 Adjusted odds ratios and 95% confidence limits of
CV morbidities in patients with the diagnosis of asthma (A) and
COPD (B). "Total” adjusted for age and sex, “Men” and
“Women” adjusted for age. p < 0.05 vs non-asthmatic (A) and
vs non-COPD (B) population.
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data confirm a higher prevalence of the diagnosis of CVD in
women with that of asthma, show that, at least in men, the
diagnosis of asthma is associated with diagnosis of angina
and coronary disease but not with that of acute or old
myocardial infarction, and do not confirm the reported
association between the diagnoses of asthma and cere-
brovascular disease.13 We must admit that we are unable to
explain why there was an association of the diagnosis of
asthma with that of angina and coronary disease but not
with that of myocardial infarction in men, although the
prevalence of the diagnosis of angina and coronary disease
and that of myocardial infarction in asthmatic men were
similar to those in men in the non-asthmatic population. It
is likely that the low number of events could have gener-
ated information that larger numbers could deny, although
again we must emphasize the breadth of our sample. In anycase, we cannot exclude that the observed increased ORs
for the diagnoses of cardiac arrhythmia and heart failure,
as well as other heart diseases, may suggest that the
consequences of those diseases on the lung could have
been confounded with asthma. However, we must stress
that we have only considered comorbidities that were
present in the same patient simultaneously with the diag-
nosis of asthma.
Another finding that is difficult to explain is the impact
of gender in the association between the diagnoses of
asthma or COPD and CVD. Several reports suggest a role for
female sex hormones in promoting the asthmatic pheno-
type.20 On the other hand, female smokers appear to be
more susceptible than male smokers to developing COPD.
Women have a more vigorous inflammatory reaction and
generate more oxidative stress in the airways than men21
likely because estrogens could cause an imbalance in the
formation and removal of toxic intermediates of cigarette
smoke components.22 All this would suggest a stronger
association between the diagnoses of asthma or COPD and
CVD in women, but often our data did not confirm it.
Soriano and colleagues1 suggested that the occurrence
of CVD events in their study was generally lower in asthma
patients compared to COPD patients likely because of the
younger age distribution. Also in our population the diag-
nosis of asthma was prevalent in younger people and this
could indicate that the age is the main association factor of
CVD in asthma or COPD. However, although an increase in
age resulted in a progressive increase in the prevalence of
the diagnoses of CVD and hypertensive disease both in the
diagnoses of asthma and COPD, the various age clusters did
not affect differently the association of the diagnosis of CV
morbidities with that of asthma, whereas cluster 3544
years was that at highest correlation with the simultaneous
presence of CV morbidities and COPD, with a progressive
significant reduction in older age clusters. Also Feary and
colleagues found that the association between diagnoses of
COPD and CVD was strongest in the younger age groups,
persisted across all ages but reduced as age increased.23
It is also difficult to explain the higher association of the
diagnosis of CVDs with the diagnosis of COPD among younger
than older patients that we have found in our study. It has
been suggested that it may be mediated by the use of
inhaled bronchodilators24 because these agents were shown
to impose a larger relative risk in people with unrecognized
CVD than in people with known disorders.25 We do not
agree with this hypothesis because our data show that
the adjusted ORs of cardiac arrhythmia, a common side
effect of bronchodilators, were almost constant in all age
clusters.
We believe that our results are interesting because they
come from a large, validated, population-based database
that illustrates what can be observed in real life and can be
considered representative of the general population. This is
the major strength of the present study. Moreover, use of
routine medical records should have eliminated differential
misclassification due to recall or interviewer bias.
The main limitations of our study are common to retro-
spective database analyses. These limitations might be
associated mainly with bias towards the selection of more
highly motivated, or better organized, practices. Conse-
quently, our findings might likely be an overestimate of the
Figure 2 Adjusted odds ratios and 95% confidence limits of CV morbidities in patients with the diagnosis of asthma or COPD in
different strata of age in years. p < 0.05 vs comorbidities in non-asthmatic and vs non-COPD population. Values adjusted for sex.
Table 3 Demographic characteristics of study population
by smoking habits, and the diagnosis of asthma or COPD (%).
General
population
Asthma COPD
Never smokers 53.62 54.98 31.23
Current-smokers 25.51 25.19 36.46
Former smokers 20.88 19.83 32.32
254 M. Cazzola et al.general picture on the one hand. Nonetheless, on the other
hand, it is well known that patients vary in their use of
health care and it is accepted that a significant proportion
of patients who are ill may not consult their doctor and this
can lead to underestimation of the problem.
Several reports have highlighted that diagnosed preva-
lence and morbidity data underestimate the total burden of
COPD because the disease is usually not diagnosed until it is
clinically apparent, and there is considerable variation inTable 4 Influence of smoking status on CV morbidities in the d
(values are expressed as rates).
Asthma vs General population
Never-
smokers
Current
smokers
Ischemic cardiopathy 1.21 1.26
Myocardial infarction 0.88 0.91
Cardiac arrhythmia 1.29 1.34
Heart Failure 1.51 1.57
Hypertension 1.13 1.17
Cerebrovascular disease 1.19 1.23
Other heart disease 1.56 1.61
Pulmonary embolism 1.53 1.59reported prevalence.26e31 This is likely due to a lack of
awareness about COPD by patients. It is only 25e50% of
COPD patients are known to their doctor.27 Patients may
well experience symptoms, but do not always present these
symptoms to their family physician.27 Poor recognition of
the disease may lead patients to believe that their respi-
ratory symptoms are nothing more than a smoker’s cough,
rather than an early sign of disease pathology, causing them
to delay contact with a healthcare professional.26 In any
case, the majority of patients with a decreased FEV1 do not
complain of any bronchial symptoms.32
Nonetheless, the underestimation of the actual burden
of COPD may also be due to the underdiagnosis of the
disease by healthcare professionals, particularly in the
early stages of the disease,33 mainly because in family
practice the diagnostic process is primarily based on
symptoms and signs presented by the patient and, conse-
quently, early-stage COPD can easily be veiled by signs of
asthma.34 Also a lack of awareness among physicians ofiagnosis of asthma or COPD related to the general population
COPD vs General population
Former
smokers
Never-
smokers
Current
smokers
Former
smokers
1.31 5.87 2.39 2.21
0.95 5.05 2.06 1.90
1.39 4.08 1.66 1.54
1.63 9.20 3.75 3.46
1.22 2.98 1.21 1.12
1.28 5.41 2.20 2.04
1.68 5.67 2.31 2.13
1.65 5.33 2.17 2.00
Table 5 Adjusted odds ratios and 95% confidence limits of
overall CV morbidities in never-smoker population with the
diagnosis of asthma or COPD related to current and former
smokers. Data are adjusted for CV morbidities.
Asthma COPD
Never-smokers/Current
smokers vs general
population
0.96
(0.80e1.13)
2.45
(1.58e3.33)*
Never-smokers/Former
smokers vs general
population
0.93
(0.76e1.10)
2.66
(1.80e3.51)*
*p < 0.05 vs general population.
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diagnosis of COPD.33,34
In any case, underestimation of the actual burden of
COPD is an important issue because it may cause a bias
when trying to study the real relationships between
diseases, a bias that register studies cannot control and
correct for.
We must highlight that GPs are faced with an array of
alternative codes for the same or similar conditions and, in
effect, practicing physicians have little faith in the accu-
racy of the ICD-9 diagnoses entered for prescription
purposes and this can question the real value of diagnoses
in the HSD. Therefore, there may have been misclassifica-
tion when our GPs have used specific diagnostic categories
and this likely because there are no standardized methods
of applying diagnostic labels in general practice. In
particular, a gender bias in the diagnosis of COPD and
asthma is to be expected when the epidemiology of
a disease makes a dramatic shift in terms of maleefemale
prevalence. Physicians are at risk for assuming COPD in men
and asthma in women.14
We did not use the lung function data for our analyses
because only one third of patients with COPD and less than
20% of those with asthma had spirometry records. This
finding fits perfectly with the results of the National
Committee for Quality Assurance (NCQA) study that sug-
gested that approximately 32% of a broad range of patients
with a new COPD diagnosis had undergone spirometry
within the previous 2 years to 6 months following diag-
nosis.35 In addition, spirometric testing appeared to
decrease with increasing age. A study that investigated the
degree of use of spirometry to establish the diagnosis of
COPD in Italy documented that many GPs do not use
spirometry to establish the diagnosis of COPD because they
think that spirometry is not necessary for the diagnosis of
COPD or there are logistical limitations to the access of the
patients to lung function laboratories.36 Regardless of
anything else, we must mention that in the analysis of
Feary and colleagues that used data from primary care to
investigate the prevalence of major comorbidities in
subjects with COPD, no clinically important difference was
seen in the results after excluding patients with COPD but
without spirometry records from the analysis.37
In conclusion, our study clearly indicates that the diag-
nosis of CVD is strongly associated with the diagnosis of
COPD and, albeit in a less strong manner, even with that ofasthma. It is clear, therefore, that there is a strong need to
look beyond the lungs in treating patients with asthma or
COPD. In any case, we must highlight that since the GPs
usually state diagnosis of COPD, asthma or CVD by using ICD
codes and a diagnosis is not true disease identification, the
relationships here presented have been described as rela-
tionship between diagnoses, and not between diseases.Conflict of interest
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